Application of Autologous and Allogeneic Platelet‐Rich Fibrin in the Repair of Chronic Wounds

ABSTRACT

Chronic wounds remain a significant clinical challenge, primarily because of persistent obstacles including prolonged healing duration, high recurrence rates, and limited responsiveness to standard therapies. These limitations impose a considerable burden, which severely affects patients' quality of life. Autologous platelet‐rich fibrin has emerged as a promising regenerative strategy to overcome these challenges; however, its clinical utility is restricted in patients with underlying conditions such as diabetic foot ulcers or impaired platelet function. In this context, allogeneic platelet‐rich fibrin has been proposed as a promising therapeutic alternative, offering distinct advantages in selected patient populations. This study provides a comparative evaluation of autologous versus allogeneic platelet‐rich fibrin in the management of persistent wounds, specifically assessing wound area reduction, granulation tissue score quality, and time of healing. Seventeen patients with prolonged, chronic non‐healing wounds were assigned to two groups: autologous platelet‐rich fibrin ( n  = 6) and allogeneic platelet‐rich fibrin ( n  = 11). Despite a significant difference in pre‐treatment wound duration (6 vs. 13 weeks, p  < 0.05), both groups showed a remarkable reduction in wound area, from a median of 7.50 to 1.25 cm ² within 2 weeks, with no statistical difference in healing rates ( p  > 0.05). Granulation tissue scores improved markedly post‐treatment, with 64.71% of patients achieving a score of 4/5, regardless of the source. Autologous platelet‐rich fibrin demonstrated a faster complete healing time (30.67 vs. 48.27 days, p  < 0.05). Treatment with allogeneic platelet‐rich fibrin on a diabetic foot ulcer resulted in an 85.7% reduction in affected area, reaching complete closure within a five‐week period. The findings show that while both groups are equally proficient in stimulating wound closure and tissue regeneration, the autologous method may accelerate the final stage of the healing process. This research encourages the broader use of allogeneic alternatives, particularly for patients with insufficient autologous blood, without compromising healing quality.